Psilocybin—the psychedelic compound that occurs naturally in certain "magic" mushroom species—has been shown in trials to ...
The FDA previously declined to approve UX111 citing CMC-related observations, but the firm is hopeful the agency will approve its new regulatory application.
The collaborative clinical study will evaluate ADSTILADRIN® (nadofaragene firadenovec-vncg) in combination with the investigational drug Ruvidar® (TLD-1433) in patients with Bacillus ...
In its effort to correlate genomic structure with gene function, the 4D Nucleome Consortium (4DN), led by Job Dekker, Ph.D., ...
Acuitas Therapeutics shelled out an undisclosed sum to acquire a majority stake in Montreal-based and privately held RNA Technologies & Therapeutics in a move to scale the latter’s operations around ...
Researchers used a panel to assess the presence of circulating tumor DNA in plasma samples and detected changes in genes related to the development of adenocarcinoma that indicated both actionability ...
First patient dosed in REVEAL pivotal trial evaluating TSHA-102 (N=15, aged 6 to <22 years) in Q4 2025, with enrollment advancing across ...
A new genetic mapping strategy reveals how entire networks of genes work together to cause disease, filling in the missing links left by traditional genetic studies. The technique could transform how ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback